Develop drug therapy treatment for chronic liver diseases. Focus on non-alcoholic steatohepatitis (NASH) treatment. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest are not shown.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company insiders made 17 open-market purchases and 0 open-market sales. Management buying with its own money is usually read as a good sign.
A loss of $8.3M against $0 in annual sales.
The stock sits at $0.13. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At last year’s rate of cash burn, the cash lasts less than a year. After that, the company needs to find new money.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
The takeaway: HEPA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.